Differential pharmacological responses of catatonia-like signs in frontotemporal dementia

Neurocase

Volumn 16, Issue 5, 2010, Pages 436-450

  Lauterbach, Edward C ^a   Kuppuswamy, Preetha Sharone ^b   Greenway, Lauren L ^c  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Antipsychotic agents; Benzodiazepines; Catatonia; Dopamine D2 receptor; Frontotemporal lobar degeneration; GABA receptors; Neurotransmitter receptors; NMDA receptors; Serotonin receptors

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMANTADINE; ARIPIPRAZOLE; CITALOPRAM; DONEPEZIL; DOPAMINE 2 RECEPTOR; LEVODOPA; LORAZEPAM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER RECEPTOR; PRAMIPEXOLE; QUETIAPINE; RAMELTEON; SEROTONIN RECEPTOR;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CATATONIA; COGNITION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; LETHARGY; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PARKINSONISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AMANTADINE; ANTIPSYCHOTIC AGENTS; BENZOTHIAZOLES; CATATONIA; CITALOPRAM; CLINICAL TRIALS AS TOPIC; DIBENZOTHIAZEPINES; DOPAMINE AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; HYPNOTICS AND SEDATIVES; INDANS; LORAZEPAM; MEMANTINE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERAZINES; PIPERIDINES; QUINOLONES; SEROTONIN UPTAKE INHIBITORS;

EID: 77956967990     PISSN: 13554794     EISSN: 14653656     Source Type: Journal    
DOI: 10.1080/13554791003623326     Document Type: Article

References (79)

1. Alisky, J. M. (2004). Is the immobility of advanced dementia a form of lorazepam-responsive catatonia? American Journal of Alzheimer's Disease and Other Dementias, 19(4), 213-214.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press.
3. Bailey, E. V., & Stone, T. W. (1975). The mechanism of action of amantadine in Parkinsonism: A review. Archives Internationales de Pharmacodynamie et de Thérapie, 216(2), 246-262.
4. Bennett Jr, J. P., & Piercey M. F. (1999). PramipexoleA new dopamine agonist for the treatment of Parkinson's disease. Journal of the Neurological Sciences, 163(1), 25-31.
5. Bialek, J., & Jarema, M. (1999). [Treatment of catatonic syndrome with fluoxetine. Case report] Psychiatria Polska, 33(1), 83-89.
6. Bobula, B., & Hess, G. (2008). Antidepressant treatments-induced modifications of glutamatergic transmission in rat frontal cortex. Pharmacological Reports, 60(6), 865-871.
7. Bobula, B., Tokarski, K., & Hess, G. (2003). Repeated administration of antidepressants decreases field potentials in rat frontal cortex. Neuroscience, 120(3), 765-769.
8. Boeve, B., Dickson, D., Duffy, J., Bartleson, J., Trenerry, M., & Petersen, R. (2003). Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. European Neurology, 49(2), 72-78.
9. Boyer, P. A., Skolnick, P., & Fossom, L. H. (1998). Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. Journal of Molecular Neuroscience, 10(3), 219-233.
10. Bowen, D. M., Procter, A. W., et al. (2008). Imbalance Implication for pharmacotherapy. Psychopharmacology (Berl), 196(4), 603-610.
11. Burstein, E. S., Ma, J., et al. (2005). Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. The Journal of Pharmacology and Experimental Therapeutics, 315(3), 1278-1287.
12. Bush, G., Fink, M., et al. (1996). Catatonia. I. Rating scale and standardized examination. Acta Psychiatrica Scandinavica, 93(2), 129-136.
13. Cardenas, V. A., Boxer, A. L., et al. (2007). Deformation based morphometry reveals brain atrophy in frontotem poral dementia. Archives of Neurology, 64(6), 873-877.
14. Carroll, B. T., Goforth, H. W., et al. (2000). The Universal Field Hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectrums, 5(7), 26-33.
15. Carroll, B. T., Goforth, H. W., & Raimonde, L. A. (2001). Partial Kluver-Bucy syndrome: Two cases. CNS Spectrums, 6(4), 329-332.
16. Carroll, B. T., Goforth, H. W., et al. (2007). Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. The Journal of Neuropsychiatry and Clinical Neurosciences, 19(4), 406-412.
17. Carroll, B. T., Kirkhart, R., et al. (2008). Katatonia: A new conceptual understanding of catatonia and a new rating scale. Psychiatry, 5(12), 42-50.
18. Chow, T. W., & Mendez, M. F. (2002). Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. American Journal of Alzheimer's Disease and Other Dementias, 17(5), 267-272.
19. Davies, R. R., Kipps, C. M., et al. (2006). Progression in frontotemporal dementia: Identifying a benign behavioral variant by magnetic resonance imaging. Archives of Neurology, 63(11), 1627-1631.
20. Deakin, J. B., Rahman, S., Nestor, P. J., Hodges, J. R., & Sahakian, B. J. (2004). Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: A double-blind randomized controlled trial. Psychopharmacology (Berl), 172(4), 400-408.
21. Dhib-Jalbut, S., Hesselbrock, R., et al. (1987). Bromocriptine treatment of neuroleptic malignant syndrome. The Journal of Clinical Psychiatry, 48(2), 69-73.
22. Diehl-Schmid, J., Förstl, H., et al. (2008). A 6-month, open-label study of memantine in patients with frontotemporal dementia. International Journal of Geriatric Psychiatry, 23(7), 754-759.
23. Fellgiebel, A., Müller, M. J., et al. (2007). Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. The World Journal of Biological Psychiatry, 8(2), 123-126.
24. Franz, M., Gallhofer, B., & Kanzow, W. T. (1994). Treatment of catatonia with intravenous biperidene. British Journal of Psychiatry, 164(6), 847-848.
25. Freedman, M. (2007). Frontotemporal dementia: Recommendations for therapeutic studies, designs, and approaches. The Canadian Journal of Neurological Sciences, 34(Suppl. 1), S118-S124.
26. Grossi, D., Fragassi, N. A., Chiacchio, L., Valoroso, L., Tuccillo, R., Perrotta, C., Rapone, P., Conchiglia, G., & Trojano, L. (2002). Do visuospatial and constructional disturbances differentiate frontal variant of frontotem-poral dementia and Alzheimer's disease? An experimental study of a clinical belief. International Journal of Geriatric Psychiatry, 17(7), 641-648.
27. Guedj, E., Allali, G., et al. (2008). Frontal Assessment Battery is a marker of dorsolateral and medial frontal functions: A SPECT study in frontotemporal dementia. Journal of the Neurological Sciences, 273(1-2), 84-87.
28. Gydesen, S., Brown, J. M., et al. (2002). Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology, 59(10), 1585-1594.
29. Hawkins, J. M., Archer, K. J., et al. (1995). Somatic treatment of catatonia. International Journal of Psychiatry in Medicine, 25(4), 345-369.
30. Huang, M., Ichiwaka, J., et al. (2006). Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl), 15(3), 274-281.
31. Imamura, T., Takanashi, M., et al. (1998). Bromocriptine treatment for perseveration in demented patients. Alzheimer Disease and Associated Disorders, 12(2), 109-113.
32. Jeong, Y., Song, Y. M., et al. (2005). Correlation of ventricular asymmetry with metabolic asymmetry in frontotemporal dementia. Journal of Neuroradiology, 32(4), 247-254.
33. Josephs, K. A., Boeve, B. F., et al. (2005). Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase, 11(4), 283-296.
34. Kagan, J., Sewell, R. A., et al. (2007). The differentiation of frontotemporal dementia from catatonia in a 43 year-old woman: Case report. McLean Annals of Behavioral Neurology, 2(1), 5-10.
35. Kasture, S. B., Mandhane, S. N., & Chopde, C. T. (1996). Baclofen-induced catatonia: Modification by serotonergic agents. Neuropharmacology, 35(5), 595-598.
36. Kertesz, A., Morlog, D., et al. (2008). Galantamine in frontotemporal dementia and primary progressive aphasia. Dementia and Geriatric Cognitive Disorders, 25(2), 178-185.
37. Kipps, C. M., Davies, R. R., et al. (2007). Clinical significance of lobar atrophy in frontotemporal dementia: Application of an MRI visual rating scale. Dementia and Geriatric Cognitive Disorders, 23(5), 334-342.
38. Kizu, O., Yamada, K., & Nishimura, T. (2002). Proton chemical shift imaging in Pick complex. AJNR. American Journal of Neuroradiology, 23(8), 1387-1392.
39. Kornhuber, J., Weller, M., et al. (1994). Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. Journal of Neural Transmission, 43(Suppl.), 91-104.
40. Lauterbach, E. C. (1998). Catatonia-like events after valproic acid with risperidone and sertraline. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 11(3),157-163.
41. Lebert, F., Stekke, W., et al. (2004). Frontotemporal dementia: A randomised, controlled trial with trazodone. Dementia and Geriatric Cognitive Disorders, 17(4), 355-359.
42. Litvan, I., Bhatia, K. P., et al. (2003). Movement Disor-ders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Movement Disorders, 18(5), 467-486.
43. Maj, J., & Moryl, E. (1992). Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. Journal of Neural Transmission Gen Sect, 88(2), 143-156.
44. Meiner, Z., Newman, J. P., Rosenman, H., Soffer, D., & Steiner, I. (2005). Frontotemporal dementia with ubiquitinated neuronal inclusions and visuospatial impairment. Neurology, 65(3), 478-480.
45. Meltzer, H. Y., Li, Z., et al. (2003). Serotonin receptors: Their key role in drugs to treat schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry, 27(7), 1159-1172.
46. Mendez, M. F. (2009). Frontotemporal dementia: Therapeutic interventions. Frontiers of Neurology and Neuroscience, 24, 168-178.
47. Mendez, M. F., & Perryman, K. M. (2002). Neuropsychiatric features of frontotemporal dementia: Evaluation of consensus criteria and review. The Journal of Neuropsychiatry and Clinical Neurosciences, 14(4), 424-429.
48. Mendez, M. F., Shapira, J. S., et al. (2007). Preliminary findings: Behavioral worsening on donepezil in patients with frontotemporal dementia. The American Journal of Geriatric Psychiatry, 15(1), 84-87.
49. Mendez, M. F., Lauterbach, E. C., et al. (2008). An evidence-based review of the psychopathology of frontotemporal dementia: A report of the ANPA Committee on Research. The Journal of Neuropsychiatry and Clinical Neurosciences, 20(2), 130-149.
50. Menza, M. A., & Harris, D. (1989). Benzodiazepines and catatonia: An overview. Biological Psychiatry 26(8), 842-846.
51. Moretti, R., Torre, P., et al. (2004). Rivastigmine in frontotemporal dementia: An open-label study. Drugs & Aging, 21(14), 931-937.
52. Neary, D., Snowden, J. S., et al. (1998). Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology, 51(6), 1546-1554.
53. Northoff, G., Steinke, R., et al. (1999). Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: Investigation of in vivo benzodiazepine receptor binding. Journal of Neurology, Neurosurgery, and Psychiatry, 67(4), 445-450.
54. Northoff, G., Kötter, R., et al. (2004). Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation. Schizophrenia Bulletin, 30(2), 405-427.
55. Parsons, C. G., Danysz, W., & Quack, G. (1999). Memantine is a clinically well tolerated N-methyl-Daspartate (NMDA) receptor antagonist a review of preclinical data. Neuropharmacology, 38(6), 735-767.
56. Paviour, D. C., Lees, A. J., et al. (2004). Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: Broadening the clinical picture to include progressive supranuclear palsy. Brain, 127(Pt 11), 2441-2451
57. Perry, R. J., Graham, A., et al. (2006). Patterns of frontal lobe atrophy in frontotemporal dementia: A volumetric MRI study. Dementia and Geriatric Cognitive Disor-ders, 22(4), 278-287.
58. Peters, F., Perani, D., et al. (2006). Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dementia and Geriatric Cognitive Disorders, 21(5-6), 373-379.
59. Ratnavalli, E., Brayne, C., et al. (2002). The prevalence of frontotemporal dementia. Neurology, 58(11), 1615-1621.
60. Rinne, J. O., Laine, M., et al. (2002). Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology, 58(10), 1489-1493.
61. Rippon, G. A., Boeve, B. F., et al. (2005). Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. Neurocase, 11(3), 204-211.
62. Rohrer, J. D., Warren, J. D., et al. (2008). Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. Archives of Neurology, 65(4), 506-513.
63. Rosebush, P. I., Hildebrand, A. M., et al. (1990). Catatonic syndrome in a general psychiatric inpatient population: Frequency, clinical presentation, and response to lorazepam. The Journal of Clinical Psychiatry, 51(9), 357-362.
64. Rosso, S. M., Donker Kaat, L., et al. (2003). Frontotem poral dementia in The Netherlands: Patient characteristics and prevalence estimates from a population based study. Brain, 126(Pt 9), 2016-2022.
65. Ruff, R. L., & Russakoff, L. M. (1980). Catatonia with frontal lobe atrophy. Journal of Neurology, Neurosurgery, and Psychiatry, 43(2), 185-187.
66. Shinagawa, S., Toyota, Y., Ishikawa, T., Fukuhara, R., Hokoishi, K., Komori, K., Tanimukai, S., & Ikeda, M. (2008). Cognitive function and psychiatric symptoms in early and late-onset frontotemporal dementia. Dementia and Geriatric Cognitive Disorders, 25(5), 439-444.
67. Snowden, J. S., Bathgate, D., et al. (2001). Distinct behavioural profiles in frontotemporal dementia and semantic dementia. Journal of Neurology, Neurosurgery, and Psychiatry, 70(3), 323-332.
68. Stephenson, C. M., Bigliani, V., et al. (2000). Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study. British Journal of Psychiatry, 177, 408-415.
69. Suzuki, K., Takano, T., & Matsuoka, H. (2007). A case of catatonia resembling frontotemporal dementia and resolved with electroconvulsive therapy. The World Journal of Biological Psychiatry, 26, 1-3.
70. Swanberg, M. M. (2007). Memantine for behavioral disturbances in frontotemporal dementia: A case series. Alzheimer Disease and Associated Disorders, 21(2), 164-166.
71. Vanderzeypen, F., Bier, J. C., et al. (2003). [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline]. L'Encéphale, 29(2), 172-180.
72. Vanhauwe, J. F., Ercken, M., et al. (2000). Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells. Psychopharmacology (Berl), 150(4), 383-390.
73. Viskontas, I. V., Possin, K. L., & Miller, B. L. (2007). Symptoms of frontotemporal dementia provide insights into orbitofrontal cortex function and social behavior. Annals of the New York Academy of Sci-ences, 1121, 528-545.
74. Weder, N. D., Aziz, R., Wilkins, K., & Tampi, R. R. (2007). Frontotemporal dementias: A review. Annals of General Psychiatry, 6: 15, 1-10.
75. Whitwell, J. L., Jack Jr, C. R., et al. (2007). Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 130(Pt 4), 1148-1158.
76. Whitwell, J. L., Jack Jr, C. R., et al. (2008). Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. NeuroImage, 39(3), 1034-1040.
77. Williams, D. R., de Silva, R., Paviour, D. C., Pittman, A., Watt, H. C., Kilford, L., Holton, J. L., Revesz, T., & Lees, A. J. (2005). Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP parkinsonism. Brain, 128(Pt 6), 1247-1258.
78. Wszolek, Z. K., Krygowska-Wajs, A., Barcikowska, M. (2003). [Fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17): Clinical criteria]. Neurologia i Neurochirurgia Polska, 37(1), 173-184.
79. Yang, C. P., Huang, W. S., et al. (2007). Diminution of basal ganglia dopaminergic function may play an important role in the generation of akinetic mutism in a patient with anterior cerebral arterial infarct. Clinical Neurology and Neurosurgery, 109(7), 602-606.